Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y
Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311
PMC: 11889221.
DOI: 10.1038/s41392-025-02124-y.
Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H
Cancer Drug Resist. 2025; 8:7.
PMID: 40051496
PMC: 11883236.
DOI: 10.20517/cdr.2024.164.
McCaffrey E, Delmastro A, Fitzhugh I, Ranek J, Douglas S, Peters J
bioRxiv. 2025; .
PMID: 40027668
PMC: 11870603.
DOI: 10.1101/2025.02.18.638923.
Zhang H, Dai J, Mu Q, Zhao X, Lin Z, Wang K
Front Immunol. 2025; 15():1491872.
PMID: 39850883
PMC: 11754191.
DOI: 10.3389/fimmu.2024.1491872.
Shojaee P, Weinholtz E, Schaadt N, Feuerhake F, Hatzikirou H
NPJ Syst Biol Appl. 2025; 11(1):3.
PMID: 39779740
PMC: 11711667.
DOI: 10.1038/s41540-024-00478-7.
The influence of hypoxia-mediated CEACAM6 upregulation on epithelial cell and macrophage response in the context of gastric cancer.
Poirah I, Chakraborty D, Dixit P, Samal S, Banerjee S, Mukherjee T
Eur J Clin Invest. 2024; 54 Suppl 2:e14352.
PMID: 39674878
PMC: 11646287.
DOI: 10.1111/eci.14352.
Ailanthone disturbs cross-talk between cancer cells and tumor-associated macrophages via HIF1-α/LINC01956/FUS/β-catenin signaling pathway in glioblastoma.
Deng X, Zhang Q, Jin F, Lu F, Duan G, Han L
Cancer Cell Int. 2024; 24(1):397.
PMID: 39639311
PMC: 11619249.
DOI: 10.1186/s12935-024-03594-w.
Extrinsic and Cell-Intrinsic Stress in the Immune Tumor Micro-Environment.
Ummarino A, Cala N, Allavena P
Int J Mol Sci. 2024; 25(22).
PMID: 39596467
PMC: 11594858.
DOI: 10.3390/ijms252212403.
Regulatory T cells in immune checkpoint blockade antitumor therapy.
Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z
Mol Cancer. 2024; 23(1):251.
PMID: 39516941
PMC: 11545879.
DOI: 10.1186/s12943-024-02156-y.
Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies.
Ciepla J, Smolarczyk R
Clin Exp Med. 2024; 24(1):235.
PMID: 39361163
PMC: 11449960.
DOI: 10.1007/s10238-024-01501-1.
Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy.
Helal I, Kamal M, Abd El-Aziz M, El Tayebi H
Expert Rev Mol Med. 2024; 26:e18.
PMID: 39320855
PMC: 11440614.
DOI: 10.1017/erm.2024.9.
The future of immunotherapy for diffuse large B-cell lymphoma.
Duell J, Westin J
Int J Cancer. 2024; 156(2):251-261.
PMID: 39319495
PMC: 11578085.
DOI: 10.1002/ijc.35156.
Tumor microenvironment and immunology of cholangiocarcinoma.
Cadamuro M, Fabris L, Zhang X, Strazzabosco M
Hepatoma Res. 2024; 8.
PMID: 39301518
PMC: 11412615.
DOI: 10.20517/2394-5079.2021.140.
NF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment.
de la Calle-Fabregat C, Calafell-Segura J, Gardet M, Dunsmore G, Mulder K, Ciudad L
Sci Adv. 2024; 10(38):eadq5226.
PMID: 39292770
PMC: 11409945.
DOI: 10.1126/sciadv.adq5226.
Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer.
Cheung S, Chan K, Senn N, Husain E, Sharma R, McGoldrick T
Int J Mol Sci. 2024; 25(17).
PMID: 39273252
PMC: 11395063.
DOI: 10.3390/ijms25179303.
Prognostic Hypoxia-Angiogenesis-Related Gene Signature in Hepatocellular Carcinoma, in Which HILPDA Contributes to Tumor Progression.
Wang S, Ye W, Yang K, Lv X, Luan J
J Inflamm Res. 2024; 17:5663-5683.
PMID: 39219818
PMC: 11365521.
DOI: 10.2147/JIR.S476388.
Integrated Analysis of Phagocytic and Immunomodulatory Markers in Cervical Cancer Reveals Constellations of Potential Prognostic Relevance.
Yordanov A, Damyanova P, Vasileva-Slaveva M, Hasan I, Kostov S, Shivarov V
Int J Mol Sci. 2024; 25(16).
PMID: 39201801
PMC: 11354974.
DOI: 10.3390/ijms25169117.
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond.
Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S
Biomark Res. 2024; 12(1):86.
PMID: 39175095
PMC: 11342599.
DOI: 10.1186/s40364-024-00637-2.
Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment.
Rosberg R, Smolag K, Sjolund J, Johansson E, Bergelin C, Wahlden J
JCI Insight. 2024; 9(19).
PMID: 39172519
PMC: 11466187.
DOI: 10.1172/jci.insight.179854.
From MASLD to HCC: What's in the middle?.
Provera A, Vecchio C, Sheferaw A, Stoppa I, Pantham D, Dianzani U
Heliyon. 2024; 10(15):e35338.
PMID: 39170248
PMC: 11336632.
DOI: 10.1016/j.heliyon.2024.e35338.